Interesting study on levothyroxine (LT4) malabsorption doi.org/10.1530/EC-22-0355 raises a number of issues.
The authors refer to 'pseudomalabsorption' without defining it although other studies refer to it as non-adherance to the drug. The study concludes that most patients performed normally during the trial - the trial data show this is not true.
The trial included ten patients from a tertiary care centre over a period of six years who were on high LT4 doses and had high to very high TSH and low fT4. It raises the question of why these patients were not sorted out long ago. If a car has a minor emissions failure it is taken off the road and the customer gets it sorted within a week or two - it seems an endocrinologist cannot perform to the same standard as a mechanic.
Although there is a subtle attempt to blame the patients the data suggests only one (patient A) may have been non-compliant. The follow-up evaluation (Table 3) shows that only two patients (A & F) achieved normal TSH, fT4. A 20% success rate, assuming they felt well also. I wouldn't use a garage that only managed to fix one in five cars.
It is claimed none of the patients have malabsorption but they needed on average 2x the normal dose of LT4. Five of the patients were identified as celiac! It is claimed five patients have 'improved hypothyroidism', this is not defined but they had TSH between 12.3 and 40.2 - no mention of symptoms. Patient B had a TSH of 40.2 with fT4 2.07 (0.95-1.57) after 33 months follow-up, no investigation into why TSH is so high with a high fT4.
The manufacturers of LT4 should have done this sort of research 40 to 50 years ago given the volume of sales.